Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Janux Therapeutics, Inc.NASDAQ: JANX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $469K fell 9.6% year over year, behind the -3.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +34.1% a year.

Context

  • Depreciation & amortization amounted to 20.3% of revenue in FY2025, up 0.8 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -9.6% toward the trailing-twelve-month pace of -3.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$469K+0.2% QoQ
Last fiscal yearDec 2025
$2.03M-1.5% YoY
LTMMar 2026
$1.98M-3.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.6%——
1 year-1.5%——
3-year CAGR+34.1%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.03M USD
Year-over-year change
-1.5%
4-year CAGR
+105.9%

Depreciation & Amortization vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.3% is the 6th highest of 10, against a peer median of -2.4%.
  • Depreciation & amortization amounts to 9.2% of revenue for JANX, versus a peer median of 5.6%.
JANX Competitors
Depreciation & Amortization for JANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$50.27M USD+111.9%+16.3%3.7%
IMTXImmatics N.V.LTM Mar 2026€12.05M EUR-2.4%+19.6%32.3%
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M USD-7.1%-22.5%4.4%
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M USD-8.9%+8.8%6.7%
IMNMImmunome, Inc.LTM Sep 2026$3.76M USD+35.4%+67.3%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M USD+10.4%+5.3%3333.9%
JANXJanux Therapeutics, Inc.LTM Mar 2026$1.98M USD-3.3%+34.1%9.2%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.03M USD-39.0%-38.3%2.9%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$468K USD-128.3%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$314K USD+2.6%+49.5%—
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —-2.4%+12.5%5.6%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Depreciation & Amortization113K841K1.96M2.06M2.03M
Deferred Income Tax00000
Stock-Based Compensation6.91M17.2M20.01M33.02M40.22M
Change in Working Capital8.84M4.28M(6.55M)685K6.71M
Accounts Receivables8M0000
Inventory831K0000
Accounts Payables2.14M(294K)277K1.58M977K
Other Working Capital(2.13M)4.57M(6.83M)(899K)5.74M
Other Non-Cash Items(169K)(2.18M)(7.69M)(10.59M)(17.57M)
Operating Cash Flow(16.98M)(42.92M)(50.58M)(43.81M)(82.24M)
Capital Expenditures(1.48M)(6.45M)(1.85M)(359K)(1.04M)
Acquisitions (Net)339.48M(64.71M)000
Purchases of Investments(473.63M)(294.39M)(317.34M)(470.58M)(705.22M)
Sales of Investments134.15M359.1M278M212.92M405.28M
Other Investing Activities(339.48M)64.71M000
Investing Cash Flow(340.96M)58.27M(41.19M)(258.02M)(300.98M)
Debt Repayment00000
Common Stock Issued204.17M500K56.53M698.27M5.29M
Common Stock Repurchased0000(347K)
Dividends Paid00000
Other Financing Activities1.81M03.02M14.97M0
Financing Cash Flow386.52M500K59.55M713.24M4.95M
Effect of Forex Changes00000
Net Change in Cash28.59M15.84M(32.22M)411.4M(378.27M)
Free Cash Flow(18.46M)(49.37M)(52.43M)(44.17M)(83.28M)

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.